Bial and GSK sign licensing agreement for COPD and asthma medicines in Portugal
Bial assumes the exclusive promotion and distribution in Portugal of Elebrato Ellipta, Laventair Ellipta, Revinty Ellipta, Trelegy Ellipta, Anoro Ellipta, and Relvar Ellipta.
GSK will remain the Marketing Authorisation Holder for the products, while Bial will act as their local representative in Portugal.
Bial and GSK have concluded an agreement for the exclusive promotion, distribution, and sale in Portugal of the medicines Elebrato Ellipta, Laventair Ellipta, Revinty Ellipta, Trelegy Ellipta, Anoro Ellipta, and Relvar Ellipta. These medicines are intended for the treatment of people with chronic obstructive pulmonary disease (COPD) and asthma.
The agreement represents an evolution of a longstanding partnership between the two companies, which already includes the promotion, distribution, and sale by Bial of Elebrato Ellipta, Laventair Ellipta, and Revinty Ellipta. With this new agreement, Trelegy Ellipta, Anoro Ellipta, and Relvar Ellipta are added to the portfolio. GSK will remain the Marketing Authorisation Holder, while Bial will serve as the local representative of these products in Portugal.
António Portela, CEO of Bial, said: “We are very pleased with this agreement, which reinforces our long-term commitment to patients living with COPD and asthma. By representing this part of GSK’s product portfolio, we are strengthening our position in the national respiratory market, which currently accounts for around 13% of our total revenue. In our growth strategy, Portugal is, and will continue to be, a market of utmost importance, and the respiratory area will play a central role. We aim to remain a trusted partner for healthcare professionals and to continue helping patients living with COPD and asthma achieve a better quality of life.”
“This agreement is, for us, a natural transition and reflects our strategy to consolidate our position as a biopharmaceutical company focused on specialty medicines, oncology, and vaccines. At the same time, we will maintain our commitment to the respiratory area by continuing our longstanding partnership with Bial, with this step representing an evolution of that relationship,” said Jeroen van der Lans, General Manager of GSK Portugal.
On 4 February 2026, the Portuguese Competition Authority adopted a decision not to oppose the transaction envisaged under this Agreement.